Most bio’s license their drugs from other companies, take $700m market cap Viking Therapeutics for eg, they license from Ligland - in phase 2 of trials no approved drugs.
They haven’t been denied anything, they were issued class 3 device, and approved device for marketing on animal sarcoma. Y90 the active ingredient is already approved and dispensed at pharmacies now...